The influence of N-linked glycans on the molecular dynamics of the HIV-1 gp120 V3 loop

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Wood, Natasha T ^a   Fadda, Elisa ^b   Davis, Robert ^c   Grant, Oliver C ^d   Martin, Joanne C ^d   Woods, Robert J ^c,d   Travers, Simon A ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c UNIVERSITY OF GEORGIA   (United States)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; MANNOSE;

ARTICLE; CONTROLLED STUDY; GLYCOSYLATION; MOLECULAR DYNAMICS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; SIMULATION; VIRAL TROPISM;

GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PEPTIDE FRAGMENTS; POLYSACCHARIDES; PROTEIN CONFORMATION;

EID: 84896716465     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080301     Document Type: Article

References (97)

1. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888. (Pubitemid 28299385)
2. Ji X, Chen Y, Faro J, Gewurz H, Bremer J, et al. (2006) Interaction of human immunodeficiency virus (HIV) glycans with lectins of the human immune system. Curr Protein Pept Sci 7: 317-324.
3. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382.
4. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, et al. (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254: 599-603.
5. Myers G, MacInnes K, Korber B (1992) The emergence of simian/human immunodeficiency viruses. AIDS Res Hum Retroviruses 8: 373-386.
6. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58: 19-42. (Pubitemid 33070762)
7. Land A, Braakman I (2001) Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. Biochimie 83: 783-790. (Pubitemid 32821244)
8. Li Y, Luo L, Rasool N, Kang CY (1993) Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 67: 584-588. (Pubitemid 23003026)
9. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312. (Pubitemid 36378357)
10. Ohgimoto S, Shioda T, Mori K, Nakayama EE, Hu H, et al. (1998) Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity. J Virol 72: 8365-8370. (Pubitemid 28421840)
11. Schonning K, Jansson B, Olofsson S, Hansen JE (1996) Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J Gen Virol 77 (Pt 4): 753-758. (Pubitemid 26121808)
12. Bolmstedt A, Hinkula J, Rowcliffe E, Biller M, Wahren B, et al. (2001) Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. Vaccine 20: 397-405. (Pubitemid 32973781)
13. Chackerian B, Rudensey LM, Overbaugh J (1997) Specific N-linked and Olinked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 71: 7719-7727. (Pubitemid 27391717)
14. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ (1999) Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73: 5294-5300. (Pubitemid 29274810)
15. Kang SM, Quan FS, Huang C, Guo L, Ye L, et al. (2005) Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 331: 20-32. (Pubitemid 39593630)
16. McCaffrey RA, Saunders C, Hensel M, Stamatatos L (2004) N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78: 3279-3295. (Pubitemid 38568268)
17. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
18. Nandi A, Lavine CL, Wang P, Lipchina I, Goepfert PA, et al. (2010) Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396: 339-348.
19. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, et al. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med.
20. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334: 1097-1103.
21. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, et al. (2007) Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 23: 415-426. (Pubitemid 46608562)
22. Pollakis G, Kang S, Kliphuis A, Chalaby MI, Goudsmit J, et al. (2001) N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem 276: 13433-13441.
23. Wilhelm D, Behnken HN, Meyer B (2012) Glycosylation assists binding of HIV protein gp120 to human CD4 receptor. Chembiochem 13: 524-527.
24. Guttman M, Kahn M, Garcia NK, Hu SL, Lee KK (2012) Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. J Virol 86: 8750-8764.
25. Zhang L, Huang Y, He T, Cao Y, Ho DD (1996) HIV-1 subtype and second-receptor use. Nature 383: 768.
26. Clapham PR, McKnight A (2001) HIV-1 receptors and cell tropism. Br Med Bull 58: 43-59. (Pubitemid 33070763)
27. Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, et al. (2009) Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 50: 259-266.
28. Keet IP, Krijnen P, Koot M, Lange JM, Miedema F, et al. (1993) Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 7: 51-57. (Pubitemid 23069032)
29. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673. (Pubitemid 26197680)
30. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877. (Pubitemid 26154590)
31. Boyd MT, Simpson GR, Cann AJ, Johnson MA, Weiss RA (1993) A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 67: 3649-3652. (Pubitemid 23143749)
32. Carrillo A, Ratner L (1996) Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol 70: 1301-1309. (Pubitemid 26029061)
33. Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, et al. (1993) Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260: 1513-1516. (Pubitemid 23273267)
34. Smyth RJ, Yi Y, Singh A, Collman RG (1998) Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J Virol 72: 4478-4484. (Pubitemid 28188761)
35. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, et al. (1996) The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 2: 1244-1247. (Pubitemid 26375410)
36. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, et al. (2004) Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 78: 524-530. (Pubitemid 37549764)
37. Sander O, Sing T, Sommer I, Low AJ, Cheung PK, et al. (2007) Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol 3: e58.
38. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, et al. (1997) Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 71: 7136-7139. (Pubitemid 27355386)
39. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, et al. (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384: 179-183. (Pubitemid 26386475)
40. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66: 6777-6780.
41. Clevestig P, Pramanik L, Leitner T, Ehrnst A (2006) CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop Nlinked glycosylation site. J Gen Virol 87: 607-612.
42. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, et al. (1992) Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 66: 3183-3187.
43. Polzer S, Dittmar MT, Schmitz H, Schreiber M (2002) The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304: 70-80. (Pubitemid 36062833)
44. Resch W, Hoffman N, Swanstrom R (2001) Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288: 51-62. (Pubitemid 32846473)
45. De Wolf F, Hogervorst E, Goudsmit J, Fenyo EM, Rubsamen-Waigmann H, et al. (1994) Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 10: 1387-1400. (Pubitemid 24382189)
46. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM (2000) Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 14: 2937-2939. (Pubitemid 32042758)
47. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388. (Pubitemid 37494331)
48. Pillai S, Good B, Richman D, Corbeil J (2003) A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19: 145-149. (Pubitemid 36308052)
49. Chang VT, Crispin M, Aricescu AR, Harvey DJ, Nettleship JE, et al. (2007) Glycoprotein structural genomics: solving the glycosylation problem. Structure 15: 267-273. (Pubitemid 46366717)
50. Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, et al. (2012) Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem 287: 24239-24254.
51. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk, Donald, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737. (Pubitemid 46279718)
52. Huang C-c, Tang M, Zhang M-Y, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028. (Pubitemid 41611916)
53. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. (Pubitemid 28289647)
54. Mao Y, Wang L, Gu C, Herschhorn A, Xiang SH, et al. (2012) Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol 19: 893-899.
55. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, et al. (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20: 796-803.
56. Durrant JD, McCammon JA (2011) Molecular dynamics simulations and drug discovery. BMC Biol 9: 71.
57. Karplus M, McCammon JA (2002) Molecular dynamics simulations of biomolecules. Nat Struct Biol 9: 646-652. (Pubitemid 34977295)
58. Woods RJ, Tessier MB (2010) Computational glycoscience: characterizing the spatial and temporal properties of glycans and glycan-protein complexes. Curr Opin Struct Biol 20: 575-583.
59. Yokoyama M, Naganawa S, Yoshimura K, Matsushita S, Sato H (2012) Structural Dynamics of HIV-1 Envelope Gp120 Outer Domain with V3 Loop. PLoS ONE 7: e37530.
60. Lopez de Victoria A, Tamamis P, Kieslich CA, Morikis D (2012) Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops. PLoS ONE 7: e49925.
61. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry 25: 1605-1612.
62. Gray ES, Moore PL, Pantophlet RA, Morris L (2007) N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol 81: 10769-10776. (Pubitemid 47463349)
63. Yang Q, Li C, Wei Y, Huang W, Wang L-X (2010) Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc. Bioconjug Chem 21: 875-883.
64. Sanders RW, van Anken E, Nabatov AA, Liscaljet IM, Bontjer I, et al. (2008) The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology 5: 10.
65. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293-7305.
66. Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, et al. (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285: 20860-20869.
67. Losman B, Biller M, Olofsson S, Schonning K, Lund OS, et al. (1999) The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. FEBS Letters 454: 47-52. (Pubitemid 29296923)
68. Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368: 145-154. (Pubitemid 47599570)
69. Case DA, Darden TA, Cheatham TE, III, Simmerling CL, et al. (2008) AMBER 10. University of California, San Francisco.
70. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725. (Pubitemid 44583220)
71. Kirschner KN, Yongye AB, Tschampel SM, Gonzalez-Outeirino J, Daniels CR, et al. (2008) GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem 29: 622-655. (Pubitemid 351238844)
72. Wehle M, Vilotijevic I, Lipowsky R, Seeberger PH, Silva DV, et al. (2012) Mechanical compressibility of the glycosylphosphatidylinositol (GPI) anchor backbone governed by independent glycosidic linkages. J Am Chem Soc 134: 18964-18972.
73. DePaul AJ, Thompson EJ, Patel SS, Haldeman K, Sorin EJ (2010) Equilibrium conformational dynamics in an RNA tetraloop from massively parallel molecular dynamics. Nucleic Acids Res 38: 4856-4867.
74. Sorin EJ, Pande VS (2005) Exploring the helix-coil transition via all-atom equilibrium ensemble simulations. Biophys J 88: 2472-2493. (Pubitemid 40976118)
75. Berendsen H vdSD, Drunen R (1995) GROMACS: a message-passing parallel molecular dynamics implementation. Comp Phys Comm 91: 43-56.
76. Hess B KC, van der Spoel D, Lindahl E (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulations. J Chem Theory Comput 4: 435-447.
77. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics 79: 926-935.
78. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A smooth particle mesh Ewald method. The Journal of Chemical Physics 103: 8577-8593.
79. Westby M, van der Ryst E (2010) CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir Chem Chemother 20: 179-192.
80. R-Core-Team (2012) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria.
81. Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38, 27-38.
82. Joao HC, Dwek RA (1993) Effects of glycosylation on protein structure and dynamics in ribonuclease B and some of its individual glycoforms. Eur J Biochem 218: 239-244. (Pubitemid 23350379)
83. Zheng K, Bantog C, Bayer R (2011) The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 3: 568-576.
84. Wang X, Kumar S, Buck PM, Singh SK (2013) Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations. Proteins 81: 443-460.
85. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113.
86. Sattentau QJ, Moore JP (1991) Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 174: 407-415.
87. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12: 1097-1106. (Pubitemid 350114990)
88. Xu S, Huang X, Xu H, Zhang C (2007) Improved prediction of coreceptor usage and phenotype of HIV-1 based on combined features of V3 loop sequence using random forest. J Microbiol 45: 441-446.
89. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682. (Pubitemid 36764500)
90. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97: 9026-9031. (Pubitemid 30626667)
91. Benson NC, Daggett V (2008) Dynameomics: large-scale assessment of native protein flexibility. Protein Sci 17: 2038-2050.
92. Carpenter EP, Beis K, Cameron AD, Iwata S (2008) Overcoming the challenges of membrane protein crystallography. Curr Opin Struct Biol 18: 581-586.
93. Kuroda D, Shirai H, Jacobson MP, Nakamura H (2012) Computer-aided antibody design. Protein Eng Des Sel 25: 507-521.
94. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, et al. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78: 1950-1958.
95. Dror RO, Dirks RM, Grossman JP, Xu H, Shaw DE (2012) Biomolecular simulation: a computational microscope for molecular biology. Annu Rev Biophys 41: 429-452.
96. Tan Q, Zhu Y, Li J, Chen Z, Han GW, et al. (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341: 1387-1390.
97. Pikora C, Wittish C, Desrosiers RC (2005) Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4. J Virol 79: 12575-12583. (Pubitemid 41346120)